

Edgar Filing: APPLIED BIOMETRICS INC - Form 10-Q

APPLIED BIOMETRICS INC
Form 10-Q
November 13, 2001

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For quarterly period ended September 30, 2001

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission File Number 0-22146

APPLIED BIOMETRICS, INC.
(Exact name of Registrant as specified in its charter)

State of Incorporation: Minnesota
I.R.S. Employer Identification No.: 41-1508112

Principal Executive Offices: P.O. Box 583457
Minneapolis, Minnesota 55458-3457
Telephone Number: (612) 338-4722

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

On November 5, 2001, there were 5,883,404 shares of the Registrant's common stock, par value \$.01 per share, outstanding.

ITEM 1. FINANCIAL STATEMENTS

APPLIED BIOMETRICS, INC.
STATEMENT OF NET ASSETS IN LIQUIDATION

Edgar Filing: APPLIED BIOMETRICS INC - Form 10-Q

	September 30, 2001 ----	December 2000 ----
ASSETS		
Cash and cash equivalents	\$ 952,876	\$ 1,109
Prepaid expenses and other current assets	10,691	85
Patents and other intangibles, net	--	23
	-----	-----
Total assets	\$ 963,567	\$ 1,218
	=====	=====
LIABILITIES		
Accounts payable	\$ 33,015	\$ 119
Other current liabilities	32,431	40
Reserve for estimated costs during period of liquidation	129,393	272
Short-term obligations	12,761	53
	-----	-----
Total liabilities	207,600	485
	-----	-----
Net assets in liquidation	\$ 755,967	\$ 732
	=====	=====

The accompanying notes are an integral part of the interim unaudited financial statements.

2

APPLIED BIOMETRICS, INC.
STATEMENT OF CHANGES IN NET ASSETS IN LIQUIDATION
JANUARY 1, 2001 THROUGH SEPTEMBER 30, 2001

Net assets in liquidation as of January 1, 2001	\$ 732,527
Change in net assets	23,440

Net assets in liquidation as of September 30, 2001	\$ 755,967
	=====

The accompanying notes are an integral part of the interim unaudited financial statements.

3

APPLIED BIOMETRICS, INC.

Edgar Filing: APPLIED BIOMETRICS INC - Form 10-Q

STATEMENT OF CHANGES IN NET ASSETS IN LIQUIDATION SEPTEMBER 1, 2000 THROUGH SEPTEMBER 30, 2000

Net assets in liquidation as of September 1, 2000	\$ 925,557
Change in net assets	(97,366)

Net assets in liquidation as of September 30, 2000	\$ 828,191
	=====

The accompanying notes are an integral part of the interim unaudited financial statements.

4

APPLIED BIOMETRICS, INC. CONDENSED STATEMENT OF OPERATIONS FOR THE PERIOD ENDED SEPTEMBER 30, 2000 (GOING CONCERN BASIS)

	EIGHT MONTHS ENDED AUGUST 31, 2000
Operating expenses:	
Selling, general and administrative	\$ 911,766
Research and development	1,500,377

Operating loss	(2,412,103)
Other income, net	57,227

Net loss	(2,354,876)
	=====
Basic and diluted net loss per share:	(0.42)
Weighted average common shares outstanding	5,655,380
	=====

Edgar Filing: APPLIED BIOMETRICS INC - Form 10-Q

The accompanying notes are an integral part of the interim unaudited financial statements.

5

APPLIED BIOMETRICS, INC.
 STATEMENTS OF CASH FLOWS
 FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2001 AND SEPTEMBER 30, 2000

	Nine Months Ended September 30,	Eight Mon Ended August 3
	2001	2000
	(Liquidation Basis)	(Going Concern Ba
CASH FLOWS FROM OPERATING ACTIVITIES:		
Increase in net assets in liquidation	\$ 23,440	
Net loss	--	\$ (2,354,
Adjustments to reconcile net loss from continuing operations to net cash used by operating activities:		
Depreciation and amortization of capital leases	--	152,
Amortization of patents and other intangible assets	--	27,
Value of common stock issued in lieu of cash compensation	--	153,
Loss (Gain) on disposal of assets	2,300	(1,
Changes in operating assets and liabilities:		
Inventories	--	167,
Prepaid expenses, other current assets and other assets	75,035	57,
Accounts payable and accrued expenses	(278,136)	(103,
Net cash used in operating activities	(177,361)	(1,890,
CASH FLOWS FROM INVESTING ACTIVITIES:		
Proceeds from sale of intangible assets, net of sale expenses	20,700	
Purchase of equipment and improvements	--	(25,
Investments in patents and trademarks	--	(19,
Net cash provided by (used in) investing activities	20,700	(45,
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from the issuance of common stock, net of expenses	--	1,490,
Proceeds from exercise of stock options	--	26,
Proceeds from capital lease obligations, net of repayments	--	(4,
Net cash provided by financing activities	--	1,512,
Net (increase) decrease in cash and cash equivalents	(156,661)	(423,
Cash and cash equivalents at beginning of year	1,109,537	1,910,

Edgar Filing: APPLIED BIOMETRICS INC - Form 10-Q

CASH AND CASH EQUIVALENTS AT END OF PERIOD	\$ 952,876	\$ 1,486,
	=====	=====

The accompanying notes are an integral part of the interim unaudited financial statements.

6

APPLIED BIOMETRICS, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS

(1) BASIS OF PRESENTATION AND LIQUIDATION BASIS OF ACCOUNTING:

The unaudited condensed financial statements of Applied Biometrics, Inc. ("Applied Biometrics" or the "Company") have been prepared by the Company in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. For further information, refer to the financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2000.

The Company adopted the liquidation basis of accounting as of September 1, 2000. This basis of accounting is considered when the liquidation of a company appears imminent and the net realizable value of its assets is reasonably determinable. Under this basis of accounting, assets and liabilities are stated at their net realizable value and estimated costs through the liquidation date are provided to the extent reasonably determinable.

7

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

CERTAIN STATEMENTS CONTAINED IN THIS FORM 10-Q INCLUDE "FORWARD LOOKING STATEMENTS" WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. THESE STATEMENTS MAY BE IDENTIFIED BY THE USE OF WORDS SUCH AS "EXPECT," "ANTICIPATE," "PLAN," "MAY," "ESTIMATE" OR OTHER SIMILAR EXPRESSIONS. SUCH STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY CAUSE THE ACTUAL RESULT TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED IN OR IMPLIED BY SUCH FORWARD-LOOKING STATEMENTS. SEE ITEM 6 "MANAGEMENT'S DISCUSSION AND ANALYSIS - CERTAIN FACTORS" IN THE COMPANY'S ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2000 FOR IMPORTANT FACTORS KNOWN TO US THAT COULD CAUSE SUCH MATERIAL DIFFERENCES.

OVERVIEW

The Company ceased its ongoing business operations in August 2000

Edgar Filing: APPLIED BIOMETRICS INC - Form 10-Q

because the Company determined it would be unable to complete the development of its primary product, the Basis System, for market and sale. The company's Chief Executive Officer resigned and all other employees were terminated. The Company has wound down its business operations, eliminated expenses and negotiated the termination or satisfaction of all of its remaining obligations.

The Company adopted liquidation basis accounting as of September 1, 2000. This basis of accounting is considered appropriate when liquidation of a company appears imminent and the net realizable value of its assets are reasonably determinable. Under this basis of accounting, assets and liabilities are stated at their net realizable value and estimated costs through the liquidation date are provided to the extent reasonable determinable.

The Company has agreed to continue to retain Manchester Companies, Inc. ("Manchester"), a Minneapolis, Minnesota investment banking firm, to manage the Company's management and accounting functions and to explore further options available to liquidate the Company. As part of the engagement of Manchester, the Company appointed James D. Bonneville as the Acting Chief Executive Officer, Chief Financial Officer and Secretary of the Company.

LIQUIDITY AND CAPITAL RESOURCES

As of September 30, 2001, net assets in liquidation were \$755,967. Cash and cash equivalents were \$952,876 as compared to \$1,110,000 at December 31, 2000, a decrease of \$157,124.

Based on its expected rate of spending, the Company believes that its existing cash and cash equivalents will be more than sufficient to fund any further expenses. The Company is presently investigating liquidation options for the Company and its shareholders. There can be no assurance that the Company will be able to find a liquidation option for the Company or the shareholders on terms satisfactory to all parties.

RESULTS OF CONTINUING OPERATIONS COMPARISON OF THE NINE MONTHS ENDED SEPTEMBER 30, 2001 WITH THE NINE MONTHS ENDED SEPTEMBER 30, 2000.

Selling, general and administrative expenses were \$118,195 for the first nine months of 2001 compared with \$911,766 during the first nine months of 2000. The Company incurred no selling costs during the first nine months of 2001. The Company incurred administrative expenses for the first nine months of 2001 that include payments of \$40,069 to Manchester, \$49,776 for insurance and other expenses and \$28,350 for legal expenses.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

APPLIED BIOMETRICS, INC. PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

Edgar Filing: APPLIED BIOMETRICS INC - Form 10-Q

None.

ITEM 3. DEFAULT UPON SENIOR SECURITIES

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

- (a) Exhibits. There are no exhibits on this quarterly report on Form 10-Q.
- (b) Form 8-K. The Company filed no Current Reports on Form 8-K for the quarter ending September 30, 2001.

9

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report signed on its behalf by the undersigned hereunto duly authorized.

APPLIED BIOMETRICS, INC.

Dated: November 12, 2001

/s/ James D. Bonneville

James D. Bonneville
Acting Chief Executive Officer
(Principal Executive Officer/Principal Financial
and Accounting Officer)

10